Gene Solutions showcased advancements in Molecular Residual Disease (MRD) and AI-powered multi-omics technologies at the Singapore Society of Oncology Annual Scientific Meeting 2025 to address precision oncology requirements in the Asia-Pacific region.

• Technology Integration: The platform combines DNA, RNA, and AI-enhanced multi-omics signals to monitor circulating tumour DNA (ctDNA) and predict primary tumour locations.
• Clinical Application: The methodology focuses on detecting cancer recurrence molecularly before imaging and tracking post-surgical residual cancer to guide follow-up strategies.
• Research Validation: Data presented includes findings published in JCO Oncology Advances and npj Breast Cancer regarding the use of ctDNA-based testing for early recurrence prediction in solid tumours.

This summary is based on a press release issued by Gene Solutions.